#871: The “Divine Leaf” with 8,000+ Years of Use — Exploring the Many Benefits of Coca with Dr. Andrew Weil and Wade Davis

Why does it matter? Because the world's drug policy is built on an openly racist lie — and the plant it buried may be safer than coffee.

The 1961 UN Convention that schedules coca alongside fentanyl and heroin was shaped by a man who announced his conclusions before his plane left New York, spent three months in the Southern Andes meeting military officials and priests, and never interviewed a single traditional coca user. That document still governs international drug policy. The World Health Organization just reaffirmed it.

Here's what the episode reveals:

• Coca's prohibition began 60 years before cocaine was even a social problem — it was colonial politics, not pharmacology, from the start
• The plant contains 14 alkaloids; cocaine is one. The other 13 have never been studied. What they produce together is categorically different from what cocaine produces alone
• Longtime users describe coca as milder than coffee, with no crash and no meaningful withdrawal — and that track record spans 8,000 years
• Coca-Cola has held the only legal UN coca import exemption since the 1961 Convention was written, proving the prohibition was selectively enforced from inception

The war on coca started 60 years before cocaine was ever a problem

The push to eradicate traditional coca fields began roughly six decades before cocaine became a social crisis. This wasn't poor timing — it was the whole point.

Wade Davis traces it to Lima's professional class looking up at the Andes, seeing poverty and illiteracy, and needing a culprit that didn't implicate the land reform or economic inequality they personally benefited from. Coca, as the central symbol of indigenous identity, served perfectly. "It had nothing to do with the pharmacology of cocaine hydrochloride," Davis says, "and everything to do with the cultural identity of the indigenous people who revered the plant."

The UN commission dispatched in the late 1940s to study the so-called coca problem runs this logic in miniature. Howard Fonda, a pharmaceutical executive, led it. He announced his conclusions before leaving New York. After three months in the Southern Andes meeting with military officials, alcaldes, government officials, and priests — not a single traditional user of the leaf — he returned with the exact same conclusions he'd arrived with.

Every enforcement action, every denied research application, every international scheduling decision since then rests on this foundation. Not toxicology reports. Not addiction data. Colonial politics dressed as science.

The man who wrote UN drug law called coca users 'barbaric' — and the WHO just reaffirmed his framework

The statutes governing international coca policy were written in language that would get their author removed from any institution today. Pablo Osvaldo Wolf, chief of the addiction-producing drugs section of the World Health Organization, wrote the coca language embedded in the 1961 UN Convention. Davis reads his actual words aloud.

"The Indio who does not chew coca leaves is clear-sighted, intelligent, and light-hearted, willing to work, vigorous, and resistant to diseases. The coquero, on the contrary, is apathetic, lazy, insensitive to his environment. His mind is befogged... Moral degeneration accompanies the physical. Lying is one of the outstanding characteristics... Criminality is high, and barbaric forms of homicide can only be explained by a certain moral insensibility."

This is not historical residue. It is active policy. The UN World Health Organization recently declined to reschedule or deschedule coca, effectively reaffirming Wolf's framework.

"Can you think of any other policy that we would live by today," Davis asks, "written by, I don't know, Herman Goring?"

Advocates pushing for rescheduling tend to lead with the science argument. That case is strong. But the pseudoscience foundation underneath it is more damning still — and naming it is rarely part of the strategy. It should be.

Coca treats both diarrhea and constipation — and that pharmacological paradox is proof the isolated compound tells you almost nothing

Andrew Weil spent years interviewing Andean communities about coca's medicinal effects. They consistently reported it treated both diarrhea and constipation. "That doesn't make any sense from the point of view of Western pharmacology," he says. Cocaine is a gut stimulant — it would worsen diarrhea, not resolve it.

But coca's other alkaloids — structurally similar to atropine and scopolamine, the gut paralytics derived from nightshade plants — appear to pull in the opposite direction. So the plant contains both. Weil's hypothesis: "When you present the body with this mix of ambivalent molecules that push and pull against physiology, the body decides what it wants to use. It may be which receptors are available for binding at the moment."

This is the model for understanding coca as a whole-plant system rather than diluted cocaine. "In coca, there are 14 alkaloids," Weil says. "Cocaine is one of them, and they all have similar chemical structures, and none of them have ever been studied. Once we isolated cocaine from the leaf, everybody lost interest in everything else."

Fourteen compounds, one studied, a century of conclusions drawn from the wrong data. The entire scientific literature on coca's pharmacology was built on a fraction of the system.

Andean populations with genes for Type 2 diabetes don't develop it — and one study showed blood sugar normalize the moment coca chewing began

High-starch diet, poor nutrition, significant genetic predisposition to Type 2 diabetes — the metabolic profile of many Andean communities should be a disaster. It isn't. Weil notes a consistent pattern: traditional diet plus coca use at altitude, and the disease doesn't materialize. Move to lower elevation, stop chewing, eat like the non-indigenous urban population, and rates climb sharply.

One study captured the mechanism in real time. Andean subjects rode exercise bikes while researchers measured blood sugar at intervals following a glucose load. "At any point in the cycle where they began to chew coca," Weil says, "blood sugar would normalize."

That study was never followed up. "If this shows potential for preventing or treating Type 2 diabetes, you know, that would be enormous," he says — which is a considerable understatement for what would be one of the highest-value targets in metabolic medicine.

Chris McCurdy at the University of Florida, currently the most active researcher in this space, just received his first legal coca leaf supply after years of regulatory navigation. Carbohydrate metabolism is one of his primary interests. The signal is there. The science is finally, barely, beginning.

Coca is a stimulant you can't feel — and Davis ran a 24-hour mountain race on it at 48

The 19th-century travel literature on coca is full of accounts like one Davis cites: the head of the British Medical Association, age 78, walks halfway across Scotland, climbs a mountain, skips meals all day, and writes at the end that it was quite a day. No sense of stimulation. Just output. "A stimulant that's not a stimulant," Davis calls it.

"You don't feel you're stimulated," Weil explains. "You just recognize the results of having been able to focus, concentrate, and remain on task. You could sit at task all day long, concentrating with immense focus, with no sense of being under the influence of any plant, nothing as harsh as a second cup of coffee."

Ferriss puts the withdrawal comparison plainly from personal experience: two or three days on modafinil creates a felt physical need when stopped. Caffeine does the same. Cocaine obviously does. "That does not happen with coca," he says. Davis puts it simply: "If I run out of coca, my life goes on. It's just not as nice a life and it's not as productive a life."

Davis's field proof: the Mojimiento, a 24-hour ritual race beginning at 11,500 feet, descending to 9,000, then climbing over 16,000 feet across two Andean ridges. He completed it at 48 — oldest and only outsider in the race's history — on more coca, he says, than anyone in 8,000 years.

The first nutritional study of coca wasn't published until 1975 — not through neglect, but to avoid finding anything good

Tim Plowman and Jim Duke's 1975 paper was the first nutritional analysis ever conducted on a plant with eight millennia of documented human use. The findings were significant: modest alkaloid content absorbed benignly through oral mucous membranes, meaningful concentrations of vitamins, proteins, more calcium than any other plant studied, and enzymes potentially enhancing carbohydrate metabolism at altitude.

This study could have been done in the 1920s.

"It wasn't done," Davis says, "because people did not want anything that would affirm the possibility that the plant was anything but the demonic entity that they claimed it to be."

The absence of coca research is not scientific oversight — it was strategic. "For a plant of such enormous historical, cultural, economic, scientific, medical importance," Weil says, "there is an almost complete absence of research on it."

For anyone in natural products, metabolic medicine, or botanical pharmacology: this is near-virgin territory. The first serious research program doesn't just fill a gap — it writes the field from scratch.

Three separate civilizations independently domesticated the same plant — and every single one immediately called it the most sacred above all others

DNA analysis traces all four cultivated coca varieties to a single wild ancestor, Erythroxylum gracilipes, growing along the eastern Andean slopes from Venezuela to Bolivia. Three separate times in pre-Columbian history, unconnected human groups found this plant and domesticated it: once in Colombia's Montaña, once in Bolivia and Peru's Yungas, and once in the northwest Amazon.

"That is unheard of," Davis says. Independent domestication events are rare in the history of plant cultivation. Three of them, converging on the same species, is essentially without precedent.

Strangest still: each time, the plant was immediately elevated to the highest sacred status. Not useful herb. Not important crop. The plant of all plants.

"To deny people coca in the Andes," Davis says, "is not like denying the Germans beer or the British tea or the French coffee. It's actually an act of cultural genocide because you cannot be runacuna" — you cannot be a person of the Andes, of Pachamama — "if you do not use the leaves."

Three independent civilizations, no contact, the same conclusion. Eight thousand years of convergent human testimony isn't anecdote. It's a signal that plant pharmacology still hasn't caught up with.

Coca-Cola has operated under the only legal UN coca exemption for over a century — and the cocaine they extract is sold for pharmaceutical use

The prohibition was never total. A single company — Stepan Chemical in Maywood, New Jersey — holds a specific exclusion written into the 1961 UN Convention on Narcotic Drugs: the only legal coca import from Peru. Stepan extracts cocaine from the leaves, sells it for pharmaceutical applications in ophthalmology and dentistry, and ships the remaining leaf extract — a proprietary secret flavoring ingredient — to Coca-Cola. "Coca-Cola notoriously had a secret coca plantation in Hawaii," Davis adds.

The same plant scheduled alongside heroin and fentanyl. The same plant that required years of regulatory navigation for Chris McCurdy to obtain enough leaves to run animal studies. One corporate exemption, named in the foundational document of international drug control, in continuous operation for over sixty years.

The UN's stated rationale for keeping coca scheduled is that cocaine could be extracted from it. That cocaine has been legally extracted from it — continuously, at commercial scale, under a UN-sanctioned arrangement, for the world's largest beverage company — does not appear to have troubled that reasoning.

The Coca-Cola exemption is the most useful rhetorical wedge in the rescheduling argument. If the plant is too dangerous to study, it is also too dangerous to flavor a soft drink. These cannot both be true.

Coca doesn't need to win a policy argument first — it needs to win a market

Weil's matcha comparison is worth holding onto. He tried for years to introduce it to American consumers and failed repeatedly, then watched it overwhelm Japan's production capacity within what felt like a season. The quality case was always there. The timing wasn't.

Coca's quality case is stronger than matcha's ever was, and the legal scaffolding already exists — Coca-Cola has operated inside it for over a century. The entrepreneur who cracks the consumer product doesn't just build a revenue stream; they build the demand that funds the research, and the research that generates the policy pressure that 60 years of science-and-justice arguments couldn't move alone.

The science will follow money faster than it follows justice. The plant has been waiting.

---

Topics: coca leaf, ethnobotany, drug policy, indigenous rights, plant medicine, whole-plant pharmacology, metabolic health, Type 2 diabetes, UN drug scheduling, Andrew Weil, Wade Davis, integrative medicine, cognitive performance, South America, prohibition history